Abbott Laboratories reports a 14% YoY increase in Q1 sales
Abbott Laboratories reported its financial results for the first quarter on Wednesday. Here's what you should know.
avatar
Khan is a professional trader and business writer with over 7 years of experience in several financial markets. Khan takes pride in sharing insightful articles with his readers that help them improve their investment portfolios.
2022-04-20 18:00

Abbott Laboratories Inc. is up 2.0% in the stock market on Wednesday after reporting its financial results for the first quarter of 2022. Abbott is a worldwide healthcare firm dedicated to assisting people at all stages of life to live more fully. With top businesses and products in diagnostics, medical devices, nutritionals, and branded generic medications, their portfolio of life-changing technology spans the healthcare spectrum.
Abbott Laboratories reports a 14% YoY increase in Q1 sales
Financial Updates
Sales of $11.9 billion in the first quarter climbed 13.8% on a reported basis and 17.5 % organically, excluding the effects of foreign exchange. In the first quarter, international nutrition sales fell 7.0% on a reported basis and 4.4% on an organic basis. A voluntary recall of some powder formulae created at one of Abbott's U.S. plants reduced sales during the quarter. GAAP diluted EPS for the first quarter was $1.37, while adjusted diluted EPS, which eliminates specific items, was $1.73. For Q1 2022, global COVID-19 testing-related sales totalled $3.3 billion.

The $215.52 billion company that trades at a PE multiple of 30.92 is down more than 10% for the year at present.

Future Outlook
Abbott maintains its full-year 2022 diluted EPS projections of at least $3.35 on a GAAP basis and at least $4.70 on an adjusted basis. The company estimates COVID-19 testing-related sales of $4.5 billion in 2022, which it expects to occur mostly in the first half of the year and will monitor on a quarterly basis.

Robert B. Ford, chairman and CEO said:

"Our diversified business continues to perform well in a challenging environment. We're particularly pleased with the strong performance we're achieving in Medical Devices and Established Pharmaceuticals."

What else was noteworthy?
Abbott announced a voluntary recall of some infant formula products made at one of its U.S. factories in February. They are collaborating with the US Food and Drug Administration (FDA) to execute corrective actions and facility improvements. Abbott's CardioMEMS HF system which is a small implantable sensor and remote monitoring system that can identify early warning symptoms of deteriorating heart failure, gained FDA approval for an extended indication in February.

Abbott stated in March that their FreeStyle Libre system is so far the only continuous glucose monitoring (CGM) device in Japan to get increased coverage for all diabetics who are using insulin. The company also received FDA approval in April for its Aveir single-chamber leadless pacemaker for the treatment of patients with sluggish cardiac rhythms in the United States. Leadless pacemakers, unlike regular pacemakers, do not need a chest incision or leads (wires) to give therapy.


Disclaimer: I have no positions in any of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. All information should be independently verified and should not be relied upon for purposes of transacting securities or other investments. See terms for more info.

Rate this article

positive
negative
Published On
2022-04-20 18:00

avatar
About the Author
Khan is a professional trader and business writer with over 7 years of experience in several financial markets. Khan takes pride in sharing insightful articles with his readers that help them improve their investment portfolios.


buy-coffee
You've read 1 article in the last year
..thank you for supporting us and for visiting our site. Unlike many other sites, The Dog of Wall Street is available for everyone to read. Our focus is to provide great content for free. Do you like what we are doing? Buy us a cup coffee. It is the fuel that keeps us going..

Is Rivian (RIVN) Stock a Buy Again?
The company continues to bleed money and is losing more than $40,000 per vehicle.
By Mike Sakuraba | 2 weeks ago

2 Stocks to Buy on a Pullback
Here are two stocks I’ll buy if we pull back in March.
By Mike Sakuraba | 2 weeks ago

2 Stocks to Buy for the March Bull Run
Here are 2 I have my eyes on for March.
By Mike Sakuraba | 3 weeks ago

Bitcoin is Hot: 2 Stocks to Buy Now
Here are 2 lesser-known crypto stocks that I think will benefit from Bitcoin’s bull run.
By Mike Sakuraba | 3 weeks ago

2 Stocks to Buy on the Earnings Dip
Here are two stocks that sold off that I have my eye on!
By Mike Sakuraba | 3 weeks ago

2 Stocks I'm Never Buying Again
Never is such a strong word but when it comes to investing, it is easy to never want to buy a stock again.
By Mike Sakuraba | 1 month ago

2 Stocks to Ride the NVIDIA Hype Train
Now that NVIDIA (NASDAQ: NVDA) saved the market again, is it finally time to buy?
By Mike Sakuraba | 1 month ago

Is it Too Late to Buy SMCI Stock?
Is it too late to get into SMCI after this parabolic run?
By Mike Sakuraba | 1 month ago